ISRCTN46615946
Completed
Phase 1
A prospective phase I/II study to evaluate the use of allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa
King's College London (UK)0 sites10 target enrollmentAugust 8, 2012
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Recessive dystrophic epidermolysis bullosa
- Sponsor
- King's College London (UK)
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
2015 results in: https://www.ncbi.nlm.nih.gov/pubmed/25905587
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who have a diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) characterised by partial or complete collagen VII deficiency
- •2\. Subjects who are \= 12 months and \= 17 years of age at the time of enrolment
- •3\. Subjects whose responsible relative/guardian has voluntary signed and dated an Informed Consent Form (ICF) prior to the first study intervention. Whenever the minor child is able to give consent, the minor's assent will be obtained in addition to the signed consent of the minor's legal guardian
Exclusion Criteria
- •Current exclusion criteria as of 10/09/2013:
- •1\. Subjects who have had other investigational medicinal products within 90 days prior to screening or during the treatment phase
- •2\. Subjects who have received immunotherapy including oral corticosteroids for more than 1 week (intranasal and topical preparations are permitted) or chemotherapy within 60 days of enrolment into this study
- •3\. Subjects with a known allergy to any of the constituents of the investigational product
- •4\. Subjects with signs of active infection
- •5\. Subjects with a medical history or evidence of malignancy, including cutaneous squamous cell carcinoma
- •6\. Subjects with both positive C7 ELISA and a positive indirect immunofluorescence (IIF) with binding to the base of salt split skin
- •7\. Subjects who are pregnant or of child\-bearing potential who are not abstinent or practicing an acceptable means of contraception, as determined by the Investigator, for the duration of the treatment phase
- •Previous exclusion criteria:
- •1\. Subjects who have had other investigational medicinal products within 90 days prior to screening or during the treatment phase
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase I, double-blind, randomized study to evaluate the safety and immunogenicity of a new Meningococcal A Conjugate vaccine versus a Meningococcal Polysaccharide A+C reference vaccine and a Tetanus Toxoid control vaccine, given as single intramuscular injections in healthy adults from 18 to 35 years of age (India)Meningococcal diseaseInfections and InfestationsISRCTN17662153Serum Institute of India Limited (SIIL) (Secondary Sponsor - Program for Appropriate Technology in Health [PATH], USA)72
Completed
Phase 2
Oral Treosulfan In Ewing's SarcomaEwing's sarcomaCancerMalignant neoplasm of bone and articular cartilage of other and unspecified sitesISRCTN11631773niversity College London (UK)21
Completed
Not Applicable
A study to examine the impact of doctor training in how to respond to patient reported symptoms and health related quality of lifeISRCTN81227579niversity of Leeds (UK)60
Completed
Phase 1
HIVIS 03: A phase I/II trial to assess the safety and immunogenicity of a plasmid DNA-MVA prime boost HIV-1 vaccine candidate among volunteers in Dar es Salaam, TanzaniaHIV-1Infections and InfestationsUnspecified human immunodeficiency virus [HIV] diseaseISRCTN90053831Swedish Institute for Infectious Disease Control (SMI) (Sweden)60
Completed
Not Applicable
The use of compression bandages in total knee replacement surgeryISRCTN86903140orthumbria Healthcare NHS Foundation Trust (UK)50